Episode Details

#GLP1 #Semaglutide #Tirzepatide #Inflammation #obesitymedicine 

GLP-1 drugs like semaglutide and tirzepatide don't just lower weight and blood sugar — the research increasingly shows they change inflammation too. In this video, Dr. Mohammed Paika (board-certified internal medicine + obesity medicine, hospitalist) breaks down what CRP actually measures, why chronic inflammation happens, how much of the anti-inflammatory effect is really just weight loss versus a separate biological pathway, and why tirzepatide's second receptor (GIP) may make it different from semaglutide.

🎓 Complete GLP-1 Weight Loss Masterclass — Lifetime Access
Comprehensive education on GLP-1 medications, nutrition, exercise, muscle preservation, side effects & long-term success. Includes the companion eBook, quizzes, 12-week exercise program, certificate & future course updates at no additional cost.
https://www.drmohammedpaika.com

📩 FREE GLP-1 Diet Cookbook + Weekly Newsletter
Get weekly evidence-based insights on GLP-1s, metabolic health, nutrition, exercise & longevity.
https://www.drmohammedpaika.com/newsletter

📚 The Weight Equation & The Physician’s Physique
Physician-written, evidence-based guides to obesity, weight loss, nutrition, metabolism, exercise, body composition & healthier living.
https://www.drmohammedpaika.com/books

👥 Metabolic Health Community
https://www.skool.com/metabolic-health-community-5316
👨‍⚕️ ABOUT DR. MOHAMMED K. PAIKA
Board-Certified in Internal Medicine and Obesity Medicine
Certified Personal Trainer & Nutrition Coach
Helping people understand metabolism, hormones, and sustainable health through evidence-based medicine.

Timestamps

0:00 Introducing the GLP-1 inflammation question
1:03 Who I am and why I'm covering this
2:54 What CRP actually measures on your labs
5:19 What inflammation really is (the alarm system)
7:35 Why visceral fat sounds a false alarm
10:23 Free GLP-1 Diet Cookbook
11:09 The puzzle: is it just weight loss?
15:01 Where the independent anti-inflammatory signal comes from
17:21 Why tirzepatide's GIP receptor might be different
20:30 What this does NOT mean (important caution)
21:34 Bringing it all together
22:42 Closing thoughts + GLP-1 Masterclass

References

Wong CK, et al. Central GLP-1 receptor activation inhibits TLR agonist-induced inflammation. Cell Metab. 2024;36(1):130-143.e5.
Ren Y, Chen Y. GLP-1 RAs and circulating inflammatory markers in T2D: meta-analysis. Diabetes Obes Metab. 2025.
Semaglutide 2.4mg and CRP in STEP 1, 2, 3: exploratory analyses. eClinicalMedicine. 2023;55:101737.
Semaglutide and hsCRP: SUSTAIN/PIONEER analyses. Cardiovasc Diabetol. 2022;21:184.
Rodbard HW, et al. PIONEER 2 Trial. Diabetes Care. 2019;42(12):2272-2281.
Semaglutide and hsCRP in SELECT: prespecified secondary analysis. PMID: 42610271.
Anti-inflammatory effects of tirzepatide: meta-analysis. Rev Endocr Metab Disord. 2025.
Sattar N, et al. Tirzepatide and hsCRP: SURPASS-4 post hoc. Circulation. 2023;148(suppl 1).
Inflammatory biomarkers with tirzepatide: SURMOUNT-1/2 post hoc. Circulation. 2024;150(suppl 1).
Wong CK, Drucker DJ. Anti-inflammatory actions of GLP-1-based therapies. J Clin Invest. 2025;135(21):e194751.'

⚕️ MEDICAL & EDUCATIONAL DISCLAIMER: This content is for general educational and informational purposes only and is not medical advice or a substitute for care from your healthcare provider. Viewing this content does not create a doctor-patient relationship. Always consult a qualified healthcare professional before starting, stopping, or changing any medication, diet, exercise, or weight-loss plan. Individual results and risks vary. You assume responsibility for decisions made based on this content.